Results 351 to 360 of about 137,029 (384)

HLADQA1*05 genotype predicts anti‐drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease

Alimentary Pharmacology and Therapeutics, 2020
Anti‐drug antibodies (ADAs) are a leading contributor to infliximab loss of response and adverse drug events. It is not feasible to identify patients at risk of antibody formation before initiating infliximab. The genetic variation HLADQA1*05 (rs2097432)
A. Wilson, C. Peel, Qian Wang, A. Pananos, R. Kim   +4 more
semanticscholar   +1 more source

Infliximab and insulin resistance

Autoimmunity Reviews, 2010
Insulin resistance is the most important pathophysiologic feature of obesity, type 2 diabetes mellitus and prediabetic states. TNF-alpha, a proinflammatory cytokine, plays a pivotal role in the pathogenesis of inflammation-associated insulin resistance during the course of rheumatic diseases.
Ursini F., Naty S., Grembiale R. D.
openaire   +3 more sources

Infliximab for the treatment of psoriasis

Expert Opinion on Biological Therapy, 2006
Psoriasis is a common immune-mediated skin disease producing significant morbidity. Tumour necrosis factor (TNF)-alpha, a pro-inflammatory cytokine, plays a key role in the cutaneous inflammation characteristic of psoriasis. Infliximab is a chimeric monoclonal antibody that specifically binds to TNF-alpha, thereby blocking its biological activity. Data
Kleyn, C. Elise, Griffiths, Christopher E M   +1 more
openaire   +3 more sources

Infliximab and ulcerative colitis

Expert Opinion on Biological Therapy, 2006
Tumour necrosis factor (TNF)-alpha is an inflammatory cytokine that plays a main role in the inflammatory process underlying inflammatory bowel disease (IBD). Despite the fact that the cytokine profiles associated with ulcerative colitis (UC) and Crohn's disease (CD) are classically considered different (a Th2 pattern in UC and a Th1 pattern in CD ...
Filippo Mocciaro, Mario Cottone, Irene Modesto   +2 more
openaire   +4 more sources

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Gastroenterology, 2015
BACKGROUND & AIMS Infliximab, a tumor necrosis factor antagonist, is effective for treating patients with Crohn's disease (CD) and ulcerative colitis (UC).
N. Vande Casteele, M. Ferrante, G. Van Assche, V. Ballet, G. Compernolle, K. van Steen, S. Simoens, P. Rutgeerts, A. Gils, S. Vermeire   +9 more
semanticscholar   +1 more source

Infliximab for psoriasis

Journal of the American Academy of Dermatology, 2003
This review summarizes the use of inflximab in psoriasis and other immune-mediated inflammatory disorders (IMIDs). The magnitude and speed of the response to infliximab monotherapy of moderate to severe psoriasis vulgaris is substantial, being similar to those achieved with cyclosporin.
openaire   +3 more sources

Infliximab for hidradenitis suppurativa

British Journal of Dermatology, 2003
Hidradenitis suppurativa (HS) is a chronic disease characterized by significant morbidity. Current medical therapies are only minimally effective at treating the disease. Infliximab is a chimeric monoclonal antibody with high affinity for tumour necrosis factor (TNF)-alpha.
Tory P. Sullivan, A.E. Burdick, Robert S. Kirsner, Francisco A. Kerdel, Esperanza Welsh   +4 more
openaire   +2 more sources

Infliximab and Adalimumab for Uveitis

Ocular Immunology and Inflammation, 2012
To describe the corticosteroid-sparing success in controlling chronic uveitis in patients treated with TNFα inhibitors.Retrospective longitudinal case series of patients started on infliximab (n = 31) or adalimumab (n = 12) for chronic noninfectious uveitis at a tertiary referral center. The main outcome was corticosteroid-sparing success.
Agnieszka Nagpal, Nisha R. Acharya, Joseph N Martel, Elizabeth Esterberg   +3 more
openaire   +3 more sources

Use of Infliximab in Pregnancy

American Journal of Gastroenterology, 2010
To the Editor: We read with great interest the article by Papa et al. (1) in the June issue of the American Journal of Gastroenterology regarding clinical settings and the use of infliximab. In Table 1, quite prominently displayed, is the recommendation that infliximab is contraindicated in pregnancy and breastfeeding.
Sunanda V. Kane, Uma Mahadevan
openaire   +3 more sources

Treatment of Sarcoidosis With Infliximab

Chest, 2005
Many patients with sarcoidosis are unable to tolerate corticosteroids or alternative therapeutic agents due to side effects or have disease refractory to these agents. We report our experience using infliximab to treat such patients.A group of patients in whom traditional sarcoidosis therapy failed, either due to drug failure or intolerable side ...
John D. Doty, Joseph E Mazur, Marc A. Judson   +2 more
openaire   +3 more sources